PML

A recent study has found Tysabri (natalizumab) treatment for two years to be efficient and safe in Japanese patients with relapsing-remitting multiple sclerosis (RRMS). The study, “Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial,” appeared in the journal…

Lemtrada (alemtuzumab) may be an effective option for relapsing-remitting multiple sclerosis (RRMS) patients withdrawing from prior treatment with Tysabri (natalizumab), an Italian study shows. The study, “High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study,” appeared in the journal Neurology and Therapy. Tysabri, an antibody with…

Relapse after First Lemtrada Course No Indication of Poor Long-Term Outcome, Study Finds Some MS patients being treated with Lemtrada report new exacerbation after they complete round one of the drug, and they wonder if this means the drug isn’t working.

A multiple sclerosis (MS) patient treated in Germany with Ocrevus (ocrelizumab) has developed the dreaded brain infection progressive multifocal leukoencephalopathy (PML). But it is not clear whether the recently approved Genentech/Roche-developed treatment is the cause. The patient took the last dose of a three-year course of Tysabri (natalizumab) in February. Tysabri is…

Many decisions to stop taking the multiple sclerosis treatment Tysabri (natalizumab) appear to be based largely on subjective factors such as patients’ or physicians’ view of the risk, rather than objective assessments of the risk, a study indicates. Tysabri is an approved immunotherapy for active relapsing-remitting multiple sclerosis (RRMS). Despite its benefits, there…

Progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with Tysabri (natalizumab) is linked to better outcomes if the condition does not give rise to actual symptoms and is diagnosed early. Limited brain lesions and more protective immune responses were also seen in patients who fared better, but researchers…

Although Tysabri (natalizumab) is a highly effective in treating patients with relapsing-remitting multiple sclerosis (RRMS), some may develop progressive multifocal leukoencephalopathy (PML). According to a new study, this occurs because Tysabri impairs immune surveillance in the central nervous system and reactivates the latent John Cunningham polyomavirus (JCV). The study, “Natalizumab Affects…

Never having been offered, let alone received any disease modifying therapy, I can address the subject of disease modifying therapies, and their side effects, with complete impartiality. Of course, the reason for the lack of any medication is because none has yet been approved for use with MS patients who…

Results from the STRIVE study support the safety of natalizumab (Tysabri) as a therapy for multiple sclerosis (MS) patients. The study, “Natalizumab in Anti-JC Virus Seronegative Patients with Early Relapsing-Remitting Multiple Sclerosis: Interim Results from the STRIVE Study,” was recently presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis…

Two studies recently published in the journal Science Translational Medicine, revealed a possible new vaccine treatment for JC virus with important implications for multiple sclerosis (MS) treatment. The studies are entitled “JC polyomavirus mutants escape antibody-mediated neutralization” and “Broadly neutralizing human…

Multiple sclerosis patients prescribed Gilenya (fingolimod) are now being informed about a handful of documented cases where the therapy was found to have led to a rare brain infection, according to the US Food and Drug Administration. The FDA has released a public warning indicating that cases of progressive multifocal leukoencephalopathy (PML) have been…